Fate New Data on CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors

 Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies

Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in Phase 1 Solid Tumor Study

Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State at Day 8 Following Treatment

https://www.globenewswire.com/news-release/2024/11/09/2977966/24675/en/Fate-Therapeutics-Highlights-Cancer-selective-HER2-Targeting-Profile-of-FT825-ONO-8250-CAR-T-cell-Product-Candidate-for-Treatment-of-Advanced-Solid-Tumors-at-2024-SITC-Annual-Meeti.html